July 07, 2020 10:31 pm | Updated 10:31 pm IST - MUMBAI
The Indian pharmaceutical sector could see an increased number of inspections/re-inspections of their facilities by the U.S. Food & Drug Administration (USFDA) to clear the overall backlog, India Ratings and Research (Ind-Ra) said in a report.
The U.S. drug regulator FDA had postponed facility inspections from April 2020 due to the COVID-19 lockdown.
This would impact new approvals and clearance for facilities.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
